Abaloparatide vs Sermorelin
Extensively Studied vs Well Studied
synergistic Mechanism-based · 47% Abaloparatide and Sermorelin work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols.
Molecular Data
Abaloparatide Sermorelin
Weight 3,960 Da 3,358 Da
Half-life ~1.7 hours 10-12 minutes
Chain 34 amino acids 29 amino acids
Type Synthetic PTHrP analog GHRH analog
Key Benefits
Abaloparatide
01 FDA-approved for osteoporosis treatment
02 Actively builds new bone (anabolic mechanism)
03 Superior hip BMD gains vs teriparatide in trials
04 Reduces vertebral fracture risk significantly
05 Reduces nonvertebral fracture risk
06 Lower hypercalcemia risk than teriparatide
07 Works through selective PTH1R activation
08 Benefits seen within 6 months
Sermorelin
01 FDA-proven efficacy
02 Maintains natural GH pulsatile patterns
03 Preserves pituitary function
04 1.26kg lean mass increase documented in elderly
05 IGF-1 mediated anabolic effects
06 Allows natural feedback regulation
Dosing Protocols
Abaloparatide
80 mcg / Once daily
Osteoporosis treatment 80 mcg Once daily
Sermorelin
200-300mcg per dose (up to 500mcg for athletic performance) / Once daily at bedtime (aligns with natural GH pulse)
Anti-aging/Longevity 200-300mcg Once at bedtime
Athletic Performance 300-500mcg Once at bedtime
Body Composition 200mcg 5 days weekly
Combination Therapy 200mcg + GHRP Once daily
Side Effects
Abaloparatide
Hypercalciuria (high calcium in urine)
Dizziness
Nausea
Headache
Palpitations
Fatigue
Upper abdominal pain
Vertigo
Injection site reactions
Sermorelin
Injection site reactions (16.7% of patients - generally mild)
Nasal irritation (intranasal route)
Contraindications
Paget's disease of bone
Prior external beam or implant radiation therapy to skeleton
Bone metastases or history of skeletal malignancies
Metabolic bone diseases other than osteoporosis
Pre-existing hypercalcemia
Pregnancy or nursing
Cumulative use exceeding 2 years lifetime
Active malignancy
Pituitary tumors
Pregnancy
Research Evidence
Abaloparatide Sermorelin
Status Extensively Studied Well Studied
References 4 studies 5 studies
Latest — November 2024
FDA Approved Yes No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.